SKETCHY USMLE Pharmacology 2025

Chapter 1. Parasympathetic (3)

1.1. Cholinomimetics

1.2. Acetylcholinesterase Inhibitors

1.3. Muscarinic antagonists

Chapter 2. Sympathetic (4)

2.1. Sympathomimetics

2.2. Indirect sympathomimetic

2.3. Alpha drugs

2.4. Beta blockers

Chapter 1. Heart Failure Drugs (3)

1.1. Digoxin, milrinone, nesiritide

1.2. ACE inhibitors, ARBs, Aliskiren

1.3. Sacubitril-Valsartan, Milrinone, Nesiritide, Ivabradine

Chapter 2. Diuretics (4)

2.1. Acetazolamide, mannitol

2.2. Loop diuretics

2.3. Thiazides

2.4. Potassium-Sparing Diuretics

Chapter 3. Antihypertensives (2)

3.1. Calcium channel blockers

3.2. Primary hypertension & hypertensive emergency

Chapter 4. Antiarrhythmics (5)

4.1. Class I A-C

4.2. Class II

4.3. Class III

4.4. Class IV

4.5. Class V

Chapter 1. Anticoagulants & Thrombolytics (4)

1.1. Heparin, LMWH, fondaparinux, direct thrombin inhibitors, Xa inhibitors

1.2. Warfarin

1.3. Antiplatelet agents

1.4. Thrombolytics

Chapter 2. Dyslipidemia Drugs (4)

2.1. Statins

2.2. Cholestyramine, ezetimibe

2.3. Fibrates, niacin

2.4. PCSK9 Inhibitors

Chapter 3. Anti-Inflammatory (4)

3.1. NSAIDs

3.2. Gout drugs

3.3. Immunosuppressants

3.4. TNF Inhibitors

Chapter 1. Vasoactive

1.1. Nitrates

1.2. Triptans & migraine

1.3. Prostaglandins, prostacyclin, bosentan, PDE5 inhibitors

Chapter 2. Allergy & Pulmonary

2.1. Antihistamines

2.2. Asthma therapy

Chapter 1. GI (4)

1.1. Antiemetic agents

1.2. H2 receptor blockers, PPIs

1.3. Laxatives & antidiarrheal agents

1.4. Antidiarrheal Agents

Chapter 2. Diabetes (2)

2.1. Insulin, sulfonylureas, meglitinides, GLP-1 agonists, DPP-4 inhibitors

2.2. Metformin, thiazolidinediones, pramlintide, SGLT2 inhibitors

Chapter 3. Thyroid, Parathyroid & adrenal (4)

3.1. Propylthiouracil, methimazole, levothyroxine

3.2. Bisphosphonates, raloxifene, denosumab, calcitonin

3.3. Teriparatide, vitamin D, cinacalcet, sevelamer

3.4. Glucocorticoids

Chapter 4. Hypothalamic & Pituitary (2)

4.1. Growth hormone, mecasermin, octreotide, pegvisomant

4.2. ADH, DDAVP, ADH receptor antagonists

Chapter 5. Sex Hormones (3)

5.1. SERMs & Aromatase Inhibitors

5.2. LHRH Agonists-GnRH Analogs

5.3. Non-Steroidal Antiandrogens (NSAAs)

Chapter 1. Anesthetics & Analgesics (5)

1.1. IV Anesthetics

1.2. Inhaled anesthetics, dantrolene

1.3. Opiates, naloxone, naltrexone

Chapter 2. Antidepressants & Anxiolytics (5)

2.1. SSRIs, SNRIs, cyproheptadine

2.2. Tricyclic antidepressants

2.3. MAO inhibitors

2.4. Bupropion, mirtazapine, trazodone

2.5. Buspirone

Chapter 3. Mood Stabilizers & Antiepileptics Drugs (5)

3.1. Lithium

3.2. Broad-Spectrum Antiepileptics

3.3. Ethosuximide

3.4. Carbamazepine, phenytoin, gabapentin, tiagabine, vigabatrin

3.5. Gabapentin & Pregabalin

Chapter 4. Antipsychotics & Parkinson’s (3)

5.1. First generation antipsychotics

5.2. Second-generation antipsychotics

5.3. Parkinsonism Drugs

Chapter 5. Psychostimulants – Narcolepsy & ADHD (2)

5.1. Narcolepsy Drugs

5.2. Amphetamine, Dexamphetamine, Lisdexamfetamine, Methylphenidate

Chapter 6. Sedative-Hypnotics (3)

6.1. Benzodiazepines & Flumazenil

6.2. Nonbenzodiazepine Hypnotics, Melatonin, Ramelteon

6.3. Barbiturates

Chapter 7. Smoking Cessation Aids (1)

7.1. Varenicline

Chapter 8. Muscle Relaxants (1)

8.1. Skeletal Muscle Relaxants

Chapter 9. Alzheimer’s Medications (1)

9.1. Alzheimer’s Disease Medications

Chapter 1. Cell Wall and Membrane Active Antibiotics

1.1. Penicillin

1.2. Nafcillin, Oxacillin, Methicillin & Dicloxacillin

1.3. Ampicillin, Amoxicillin, Piperacillin, Ticarcillin

1.4. Cephalosporins

1.5. Monobactams & Carbapenems

1.6. Vancomycin

1.7. Daptomycin

Chapter 2. Inhibitors of Bacterial Protein Synthesis

2.1. Tetracyclines

2.2. Macrolides

2.3. Clindamycin

2.4. Chloramphenicol

2.5. Linezolid

2.6. Aminoglycosides

Chapter 3. Antimycobacterials

3.1. Tuberculosis Drugs

3.2. Leprosy drugs

Chapter 4. Other Antibiotics

4.1. Trimethoprim-Sulfamethoxazole

4.2. Fluoroquinolones

4.3. Metronidazole

Chapter 5. Antifungals

5.1. Amphotericin, flucytosine

5.2. Azoles

5.3. Griseofulvin, Terbinafine, Echinocandins

Chapter 6. Antivirals HIV

6.1. NRTIs

6.2. NNRTIs

6.3. Protease inhibitors

6.4. Maraviroc, fusion inhibitors, integrase inhibitors

Chapter 7. Antivirals Hepatitis

7.1. Acyclovir, valacyclovir, famciclovir

7.2. Ganciclovir, valganciclovir, foscarnet, cidofovir

Chapter 1. Antimetabolites

1.1. Methotrexate, leucovorin, 5-fluorouracil, hydroxyurea

1.2. Azathioprine, 6-mercaptopurine, mycophenolate mofetil

1.3. Cladribine, cytarabine, gemcitabine

Chapter 2. DNA & Cellular Division

2.1. Cyclophosphamide, ifosfamide, busulfan, nitrosoureas (carmustine, lomustine, streptozocin)

2.2. Cisplatin, carboplatin, oxaliplatin, amifostine

2.3. Bleomycin, doxorubicin, daunorubicin, actinomycin D

2.4. Etoposide, teniposide, topotecan, irinotecan

2.5. Vincristine, vinblastine, paclitaxel

Chapter 3. Kinase Inhibitors & Monoclonal Antibodies

3.1. Imatinib, erlotinib, sorafenib, sunitinib, vemurafenib

3.2. Rituximab, cetuximab, bevacizumab, alemtuzumab, trastuzumab

Chapter 1. Pharmacokinetic Basics (2)

1.1. Membranes – Partition Coefficient, Passive Diffusion, and Active Transport

1.2. Plasma Concentration & Therapeutic Range

Chapter 2. Absorption (2)

2.1. Oral Drug Absorption & Bioavailability (F)

2.2. Intro to Drug Absorption via Parenteral Routes

Chapter 3. Distribution (2)

3.1. Drug Distribution & Protein Binding

3.2. Volume of Distribution

Chapter 4. Metabolism (2)

4.1. Intro to CYP450 Enzymes

4.2. P-Glycoprotein & Enterohepatic Recycling

Chapter 5. Elimination (2)

5.1. Clearance & Area Under the Curve

5.2. Elimination-Rate Constant, Half-Life, Steady State

Chapter 6. Pharmacodynamic Basics (1)

6.1. Agonists, Antagonists, Allosteric Modulators 

Chapter 7. Drug-Drug Interactions (1)

7.1. Intro to Pharmacodynamic & Pharmacokinetic Drug Interactions